uniQure (NASDAQ:QURE) Shares Up 9.9% – Should You Buy?

uniQure (NASDAQ:QURE)’s stock price shot up 9.9% during trading on Monday . The stock traded as high as $14.24 and last traded at $14.29. 583,533 shares traded hands during trading, a decline of 67% from the average session volume of 1,745,626 shares. The stock had previously closed at $13.00.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Wells Fargo & Company decreased their price target on uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Chardan Capital initiated coverage on shares of uniQure in a report on Tuesday, April 1st. They set a “buy” rating and a $38.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. StockNews.com raised uniQure to a “sell” rating in a research report on Tuesday, March 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of uniQure in a report on Monday. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $38.80.

uniQure Price Performance

The business’s 50 day simple moving average is $11.91 and its 200-day simple moving average is $11.40. The stock has a market capitalization of $778.17 million, a price-to-earnings ratio of -2.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

Insider Transactions at uniQure

In related news, CEO Matthew C. Kapusta sold 6,717 shares of uniQure stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $76,036.44. Following the sale, the chief executive officer now directly owns 580,795 shares in the company, valued at $6,574,599.40. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Christian Klemt sold 2,916 shares of the company’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the sale, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at $1,756,501.76. The trade was a 1.84 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 90,830 shares of company stock worth $961,401. Company insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in QURE. Twin Tree Management LP bought a new position in uniQure during the 4th quarter valued at $77,000. FNY Investment Advisers LLC bought a new position in uniQure during the fourth quarter valued at about $88,000. ADAR1 Capital Management LLC acquired a new position in uniQure during the fourth quarter worth about $177,000. China Universal Asset Management Co. Ltd. raised its position in uniQure by 9.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock worth $195,000 after acquiring an additional 969 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in uniQure by 13.9% in the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 1,503 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.